Bone Cancer (Residuals)

DC 5012 verbatim NOTE — 100% rating for active malignant bone neoplasm (during/after surgical, X-ray, antineoplastic chemotherapy, or other therapeutic procedure). The 100% rating continues for six months beyond the cessation of treatment; mandatory VA examination at the expiration of six months. Any rating change is subject to § 3.105(e). If no local recurrence or metastasis, rate-as residuals under the appropriate musculoskeletal DC for the affected bone (limitation of motion at the affected joint, prosthesis DC 5051-5056 if joint replacement performed, amputation DC 5120-5173 if amputation performed, scar/disfigurement under § 4.118).

Post-treatment residuals — severe: rate-as severe limitation of motion (DC 5200-5275 range depending on joint), or severe amputation residual, or marked weakness/atrophy under the appropriate muscle group DC. Specific tier depends on affected bone/joint.

Post-treatment residuals — moderate: rate-as moderate limitation of motion or moderate amputation residual under the appropriate DC.

Post-treatment residuals — mild: minimum compensable rating per the underlying musculoskeletal DC (typically 10% for painful motion or compensable limitation).